Judge denies motion to block Exubera sales

Share this article:
A federal judge in New York on Thursday denied a motion filed by Novo Nordisk that would have blocked sales of Pfizer’s inhaled insulin Exubera. The preliminary injunction was requested by Novo Nordisk as part of a patent infringement case that will be heard by the same court. Novo sued Pfizer in August saying that sales of Exubera would damage future sales of Novo’s developmental inhalable insulin product AERx, projected for release in 2011. In a ruling, Judge Leonard Sand said Novo’s claims were “speculative” and that halting Exubera sales would be “contrary to the public interest.” In his 13-page ruling, Sand said a determination of the validity of the patents “will best be served through closer inspection at trial.” Jim Shehan, Novo’s general counsel for North America told Reuters the drug maker remained confident in the strength of its patents. “We intend to keep moving forward to trial and our intention in not weakened by the way in which the judge ruled in this case,” Shehan said. No trial date has been set for the patent infringement case.
Share this article:
close

Next Article in News

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.